Hydroquinone Prices Recover After Period of Oversupply

12 October 1998 00:00  [Source: ICB Americas]

By Feliza Mirasol

Prices for hydroquinone are increasing for the first time in three years as the market tightens and growth continues at a steady pace. US producers say supply and demand are more balanced than they were last year, and the industry is moving prices back to previous levels to keep the business healthy.

Rhodia Inc., a wholly owned subsidiary of RhÖne-Poulenc SA and one of the major hydroquinone producers in the US, has raised global prices for all grades of its hydroquinone products by 12 percent.

The softness in pricing was due, in part, to Rhodia's expansion in 1995, which added significant capacity to the market, according to John Pannucci, director of Rhodia's North American business unit for diphenols and aromas.

"The capacity we added did contribute to some price softness, but we find now that our volumes are very strong on a worldwide basis. We are trying to return to previous price levels to recoup the investments we made in process improvements, environmental safety and capacity additions during the past three years as they were needed to follow market demand," Mr. Pannucci says.

Rhodia is not undertaking additional expansions, having recently completed a series of debottleneckings begun in 1995 at its hydroquinone and hydroquinone derivatives plants in Baton Rouge, La., and St. Fons, France.

"Rhodia is unique in that it has two manufacturing facilities," says Mr. Pannucci. The company reports strong sales despite the added capacity.

"While we have the ability to increase our hydroquinone capacity further, we don't see that [new] capacity is needed. We believe there is enough capacity available in the world [market] today by all of the suppliers to satisfy [current global] demand, and possibly for the next two years," Mr. Pannucci notes.

Rhodia operates on a global basis and offers more than 80 percent of its hydroquinone products on the merchant market.

In July, Eastman Chemical Company, another leading US producer of hydroquinone, raised its off-list prices for photographic-grade hydroquinone by 10 cents per kilogram for domestic sales and 15 cents per kilogram for international sales (CMR, 6/15/98, pg. 16).

Like Rhodia, Eastman sees no reason to raise capacity despite the market's tightening.

"We have not undergone expansion and have no current plans to increase capacity," says Jeff Presley, Eastman's business market manager for organic intermediates.

"The current level of global supply matches the level of consumption. We currently have 25 million pounds of dedicated capacity to produce photographic-grade and USP-grade hydroquinone, which are the highest quality-grades of hydroquin-one in the marketplace." Eastman's hydroquinone plant is in Kingsport, Tenn.

Growth in the hydroquinone market is steady, producers say. According to Menlo Park, Calif.-based SRI Consulting, overall US consumption should grow at an average annual rate of 3 to 5 percent to the year 2000. Based on this, total US consumption will exceed 44 million pounds by the end of the year, up from 41 million pounds in 1995.

The primary applications for hydroquinone are rubber antioxidants, intermediates, photographic processing and polymerization inhibitors. Both Rhodia and Eastman cite polymerization inhibitors as the strongest market for hydroquinone at a 3 to 4 percent annual growth rate.

Eastman is seeing a decrease in this segment's growth rate because of the Asian crisis, but the company says that, as a whole, it is not seeing a "large impact" from that crisis.

Photographic processing chemicals are also a substantial end market for hydroquinone, which is used as a developing agent in silver halide photography.

Fairfield, N.J.-based consultant Kline & Co. estimates the overall US market for silver halide films, papers and photofinishing formulations at slightly more than $1 billion in 1997, excluding film and resin coatings. Photofinishing formulations, including hydroquinone and a variety of other chemicals, account for nearly $400 million of that total.

ALITRETINOIN--San Diego, Calif.-based Ligand Pharmaceuticals Inc. has filed a New Drug Submission (NDS) with the Health Protection Branch (HPB) of Canada for Panretin gel (alitretinoin) 1 percent for the treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma (KS). Canada has accepted the NDS for priority review. The company says that if it is approved by HPB, Panretin gel will be the first topical therapy in Canada for KS, which is a common cancer in people with AIDS.

CLONAZEPAM--Pittsburgh-based Mylan Laboratories Inc. has received Food and Drug Administration approval to manufacture and market clonazepam tablets in 0.5, 1 and 2 milligram strengths. The product will be produced in Mylan's Morgantown, W.Va., facility, and shipment will begin shortly. Clonazepam is the generic version of Klonopin, a benzodiazepine product manufactured by Roche Laboratories Inc. for the treatment of panic and seizure disorders.

CODEINE--Bradley Pharmaceuticals Inc. (BradPharma), Fairfield, N.J., has acquired Procter & Gamble Pharmaceuticals' Brontex product line, including the Brontex trademark and existing inventories. Brontex, a cough suppressant containing the active ingredients codeine phosphate and guaifenesin, will be marketed by BradPharma's Kenwood Therapeutics division.

CULTOR FOOD SCIENCE INC., Ardsley, N.Y., will market Tarrytown, N.Y.-based AMBI Inc.'s Cardia Salt Alternative as a food ingredient to the US processed food industry. Cultor will represent the product exclusively for use in packaged food products that are distributed and sold through all retail store channels. The alliance is AMBI's second distribution agreement concerning its Cardia Salt Alternative.

Last month, the company granted American Home Products Corporation's Whitehall-Robins Healthcare Division an exclusive license to sell Cardia Salt Alternative as a table-top product in US retail markets.

ELAN CORPORATION PLC, Dublin, Ireland, has granted Schwarz Pharma Inc., the US affiliate of Monheim, Germany-based Schwarz Pharma AG, exclusive US marketing and distribution rights for Verelan and Verelan PM, following Elan's recent re-acquisition of the Verelan franchise from AHP's Wyeth-Ayerst Laboratories division. Verelan is Elan's spheroidal oral drug absorption system (SODAS) formulation of the calcium channel blocker verapamil (anti-hypertension).

Under the agreement, Schwarz will immediately begin marketing and distributing Verelan and will expand its 275-person sales force. Elan will manufacture both products and supply them to Schwarz.

GERON CORPORATION, Menlo Park, Calif., has received a UK patent covering claims broadly directed at the key catalytic protein component of human telomerase. Geron co-owns the patent with the University Technology Corporation at the University of Colorado, Boulder.

GUAR GUM--The Aqualon division of Hercules Inc. will raise list prices for guar and guar derivative products by 5 to 10 percent, effective November 1. The company attributes the increase to rapidly escalating raw material costs caused by tight supplies and continued strong demand for guar products. Deficient rainfall in a significant portion of the guar-growing region resulted in reduced harvest projections for the 1998 crop.

THE INDENA GROUP, Milan, Italy, a global leader in botanical active principles for the pharmaceutical, cosmetic and healthcare industries, has finalized its acquisition of the majority of Bernet S.p.A., a botanical extracts company belonging to ResPharma S.r.l.

In addition to the stock exchange, Res-Pharma will continue its distribution activity and its agency for the Bernett products at an international level. As a result of the acquisition, Indena now employs more than 600 people in Europe at its offices in Milan, its research center in Settala, its production sites in Settala and Tours, France, and the Bernett plant in Palestro.

LETEPRINIM POTASSIUM--Ir-vine, Calif.-based NeoTherapeutics Inc. and its partner, Providence, R.I.-based Clinical Studies Ltd., a wholly owned subsidiary of PhyMatrix Corporation, have met patient enrollment objectives regarding a Phase II clinical trial for Neotrofin (AIT-082, leteprinim potassium) for the treatment of symptoms associated with mild to moderate Alzheimer's Disease.

SODIUM ERYTHORBATE--PMP Fermentation Inc., Itasca, Ill., is offering Eribate (sodium erythorbate) to extend the shelf life of meat snacks. Eribate, which according to the company, has long been used as a cure accelerator in cured meats, also serves as an antioxidant, enhancing color retention and inhibiting oxidation.

TRIANGLE PHARMACEUTICALS Inc., Durham, N.C., has received a US patent for beta-21-deoxy-5-fluoro-31-thiacytidine, also known as FTC, developed by Emory University. Triangle Pharmaceuticals entered into a licensing agreement with Emory in April 1996 under which Triangle received an exclusive global license to all of Emory's rights to purified forms of FTC in the HIV and HBV fields.

< previous article(VIDEO - ICIS news Asia Lunchtime Bulletin 16 October 2009)

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly